Viridian Therapeutics(NASDAQ) VRDN

Viridian Therapeutics, Inc. makes medicines for rare diseases. Its treatments help patients with eye swelling and vision loss. These products work at home or in medical clinics.

Treatments for Rare Diseases

• IGF-1R Therapies: Includes the FDA-approved medicine veligrotug for thyroid eye disease; targets a biological pathway to treat eye swelling and pain.
• Subcutaneous Candidates: Features elegrobart, an investigational drug designed for self-administration at home using an autoinjector device.
• FcRn Inhibitors: Early-stage proteins designed to treat autoimmune disorders by lowering certain antibodies that can cause disease.
• TSHR Inhibitors: Antibodies under development for Graves' disease; targets a receptor that triggers excessive thyroid hormone production.

Strategic Moves and Alliances

• Received FDA approval for veligrotug in June 2026 for the treatment of thyroid eye disease.
• Licensed development and commercial rights for products in Japan to Kissei in July 2025.
• Partnered with Zenas BioPharma and Zai Lab to develop antibody products for the China market.
• Completed a $250.0 million public offering of convertible senior notes in May 2026 to fund operations.

Scientific Innovation and Commercial Reach

Viridian improves treatments by making them easier for patients to use at home through subcutaneous injections. The company builds its own commercial teams while using global partners to reach international markets in Japan and China.

A Look at the Numbers

• Net loss was $127.1 million for the three-month period ended June 30, 2026.
• Cash, cash equivalents, and marketable securities totaled $981.5 million as of June 30, 2026.
• Selling, general and administrative expenses rose to $55.0 million in Q2 2026, up $34.8 million year over year.
• Research and development expenses were $71.6 million for the quarter ended June 30, 2026.

Evolution and Future Focus

Viridian has evolved from a research firm into a commercial company with its first approved drug. Its strategy focuses on advancing a diverse pipeline of autoimmune therapies while maintaining a strong cash position.